During 2023, the Steritas team had the opportunity to speak with a range of inspiring clinical research leaders who shared their expertise with us and our colleagues. Every conversation underscored ...
Although ongoing research continues to advance our understanding of IgG4-related disease (IgG4-RD), the epidemiology and downstream consequences of this relatively rare and complex autoimmune ...
Ever since the introduction of the Steritas Glucocorticoid Toxicity Index (GTI) in 2017, there has been a remarkable surge in the number of clinicians and clinical researchers using Steritas's ...
A new study published in the New England Journal of Medicine shows the incidence of cardiovascular disease correlates strongly with the four metabolic domains used in the Steritas GTI-MD (body mass ...
A challenge that has vexed health systems and payers for decades is the inability to fully quantify the long-term impacts of steroid-toxicity. Set to change that paradigm is the GTI-MD, an ...